Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can artificial intelligence (AI) play a role in mitigating disparities with breast cancer screening?
For the multicenter study, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), researchers evaluated the ProFound AI Breast Health Suite (iCAD) for assessing short-term breast cancer risk based on digital breast tomosynthesis (DBT) images for 3,558 women. The cohort included 394 cases of breast cancer detection, according to the study. For the ProFound AI Breast Health Suite, one-year AI risk scores < 34 percent denote average risk, scores between 34 percent and 60 percent reveal intermediate risk and scores > 60 percent are considered high-risk scores.
Here one can see a non-spiculated mass on the upper left mammography image for a 62-year-old Black woman who had scattered fibroglandular densities at initial screening and a grade 3 invasive ductal carcinoma detect in subsequent mammography screening (upper right) with the AI detection score (below) increasing from 37 to 85. (Images courtesy of 2024 San Antonio Breast Cancer Symposium (SABCS) and iCad.)
Overall, women with intermediate risk scores comprised 13.1 percent of the cohort, high-risk scores accounted for 18.2 percent of the study participants and the remaining 68.7 percent of the cohort had average risk scores.
While acknowledging differences in the racial composition of the adjusted high-risk screening population, the study authors noted similarities in breast cancer prevalence for those who had high AI one-year risk scores. In this group, the researchers pointed out a 1 in 38 prevalence of breast cancer in White women, a 1 in 41 prevalence in Black women, a 1 in 34 prevalence for Asian women and a 1 in 55 prevalence for women of other races.
“The case scores did not vary significantly across racial subgroups in our dataset, suggesting that the accuracy of the AI software was consistent across races,” noted Chirag Parghi, M.D., M.B.A., the chief medical officer for Solis Mammography.
The study authors also noted similarities in AI high-risk scoring between women with dense breasts and those with non-dense breasts. For women with dense breasts and high AI risk scores, the breast cancer prevalence was 1 in 36 in comparison to a 1 in 41 prevalence for women with non-dense breasts and high AI risk scores, according to the researchers.
“Based on our results, image-based risk can potentially offset known gaps in breast cancer detection by traditional mammography in patients with dense tissue and address known disparities across races,” emphasized Parghi and colleagues.
Reference
1. Parghi C, Pantleo J, Shisler J, et al. Image-derived short term breast cancer risk score in the analysis of breast cancer prevalence in screening population by race and breast density. Poster presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) December 10-13, San Antonio, Texas.
Recent Videos
Related Content
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025Article
In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Article
Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Article
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
